Tonix Pharmaceuticals Holding Corp. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

SALE AND PURCHASE OF COMMON STOCK (Details Narrative)

SALE AND PURCHASE OF COMMON STOCK (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	Jul. 31, 2024	Apr. 02, 2024	Mar. 28, 2024	Dec. 20, 2023	May 12, 2025	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2024	Sep. 30, 2024	May 22, 2024	Jan. 25, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Stock offering expenses						$ 2,270	$ 0
Common stock, authorized						1,000,000,000		1,000,000,000	1,000,000,000			1,000,000,000	160,000,000
Shares repurchased						250,000
Price per share						$ 12.15
Cost of repurchased shares						$ 3,047
2024 Share Repurchase Program [Member]
Class of Stock [Line Items]
Share repurchase authorized amount										$ 10,000
Shares repurchased						250,000
Cost of repurchased shares						$ 3,047
2024 Share Repurchase Program [Member] \| Minimum [Member]
Class of Stock [Line Items]
Price per share						$ 9.98
2024 Share Repurchase Program [Member] \| Maximum [Member]
Class of Stock [Line Items]
Price per share						$ 14.33
Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of warrants exercised							4,701
Common Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants		2,172
Exercise price		$ 1,056.00									$ 1,056.00
Termination date		Apr. 01, 2029
Common Warrants Series A [Member]
Class of Stock [Line Items]
Number of shares for common warrants		2,782
Termination date		Apr. 01, 2029
Common Warrants Series B [Member]
Class of Stock [Line Items]
Number of shares for common warrants		2,782
Termination date		Apr. 01, 2025
Common Warrants Series C [Member]
Class of Stock [Line Items]
Number of shares for common warrants		10,884
Termination date		Apr. 01, 2026
Period of trading days after FDA acceptance of NDA for warrant expiration		10 days
Common Warrants Series D [Member]
Class of Stock [Line Items]
Number of shares for common warrants		10,884
Termination date		Apr. 01, 2029
Subsequent Event [Member] \| 2024 Share Repurchase Program [Member]
Class of Stock [Line Items]
Cost of repurchased shares					$ 2,900
Shares repurchased					150,000
Subsequent Event [Member] \| 2024 Share Repurchase Program [Member] \| Minimum [Member]
Class of Stock [Line Items]
Price per share					$ 18.25
Subsequent Event [Member] \| 2024 Share Repurchase Program [Member] \| Maximum [Member]
Class of Stock [Line Items]
Price per share					$ 20.47
Sales Agreement [Member]
Class of Stock [Line Items]
Number of shares issued			3,365
Net proceeds			$ 3,900
Price per share			$ 960.00
Stock offering expenses			$ 500
Placement agent fees			$ 300
Offset to proceeds from issuance of warrants									$ 3,000
Sales Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants			1,219
Price per share			$ 959.68
Sales Agreement [Member] \| Common Warrants Series E [Member]
Class of Stock [Line Items]
Number of shares for common warrants			4,584
Exercise price			$ 1,056.00
Warrants term			5 years 6 months
Sales Agreement [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued					600,000
Net proceeds					$ 9,900
Sales Agreement [Member] \| Alliance Global Partners [Member]
Class of Stock [Line Items]
Offering price per agreement	$ 250,000
Commission to agent	3.00%
Number of shares issued								2,700,000
Net proceeds								$ 59,800
Sales Agreement [Member] \| Alliance Global Partners [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued					600,000
Net proceeds					$ 9,900
Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued				7,920
Stock offering expenses				$ 2,300
Proceeds from equity offerings				$ 30,000
Purchase Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants				8,973
Exercise price				$ 0.32
Price per share				$ 1,775.68
Number of warrants exercised				2,034
Purchase Agreement [Member] \| Common Warrants [Member]
Class of Stock [Line Items]
Price per share				$ 1,776.00
Purchase Agreement [Member] \| Common Warrants Series C [Member]
Class of Stock [Line Items]
Number of shares for common warrants				25,338
Exercise price				$ 1,776.00
Warrants term				2 years
Period of trading days after FDA acceptance of NDA for warrant expiration				10 days
Common stock, authorized for warrant exercise													1,000,000,000
Period of trading days after approval date to become exercisable				10 days
Purchase Agreement [Member] \| Common Warrants Series D [Member]
Class of Stock [Line Items]
Number of shares for common warrants				25,338
Exercise price				$ 2,720.00
Warrants term				5 years
Purchase Agreement [Member] \| Equity Classified Common Warrants D [Member]
Class of Stock [Line Items]
Number of shares for common warrants				15,917
Stock offering expenses				$ 1,400
Purchase Agreement [Member] \| Liability Classified Common Warrants C and D [Member]
Class of Stock [Line Items]
Number of shares for common warrants				9,422
Stock offering expenses				$ 900